The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA has controversially granted accelerated approval to aducanumab and has opined that the reduction of amyloid is reasonably likely to predict clinical benefit 7,9,[98][99][100][101][102][103][104][105][106][107] .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 2×
“ing anti-Aß monoclonal antibodies including lecanemab [9], gantenerumab [10], and donanemab [11] and the many”
BackgroundSelf-citationSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847
Self-citationStructural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 369
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J. L., Feldman, H., & Scheltens, P. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 252
Self-citationAlexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240
Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
IMMEDIATE CARE OF ACUTE BLUNT LARYNGEAL TRAUMA
Nahum, A. M. (1969) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-196902000-00003 · Cited by 57
Sabbagh, M. N., & Cummings, J. L. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12235 · Cited by 47
Self-citation
Research works printed but not linked: 2
- Haeberlein SB, von Hehn C, Tian Y, et al., editors. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. San Diego, CA: 12th Clinical Trials on Alzheimer's Disease; 2019.
- Food and Drug Administration, Center for Drug Evaluation and Research. Formal meetings between the FDA and sponsors or applicants of PDUFA Products Guidance for Industry. Silver Spring, MD: Office of Communictions, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration; 2017.
Cited by
Sorted by citations
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Cummings, J. L., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2023) · BioDrugs · doi:10.1007/s40259-023-00633-2 · Cited by 420
Self-citationJeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293
Cummings, J. L. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 266
Self-citation
Metadata
- Authors
- Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S.
- Affiliations
- University of Nevada, Las Vegas (US)
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- Cleveland Clinic (US)
- Brown University (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's Research & Therapy
- Published
- 2021-05-10
- Volume
- 13
- Issue
- 1
- Pages
- 98-98
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC8111757
- OpenAlex
- W3161140821
- Cited by
- 224
- References
- 19
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 31 · 2023: 52 · 2022: 87 · 2021: 31
- FWCI
- 31.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- National Institute on Aging (R01AG053798, P20AG068053, R35AG71476)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- aducanumab, amyloid-beta, Alzheimer's disease, anti-amyloid therapy, clinical benefit
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Amyloid beta-Peptides, Amyloidogenic Proteins, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
